

## DAFTAR PUSTAKA

- Bash, E., 2015. Antimicrobial resistance. *PhD Proposal*. Available at: <http://www.who.int/mediacentre/factsheets/fs194/en/>.
- Bhavanam, P.R., Lekkala, V.K., Maddirala, P., Reddy, S.N., Krishna, A.S. & Rajesh C.H., 2010. Formulation and evaluation of levofloxacin using different types and concentrations of superdisintegrants. *Journal of Pharmaceutical Sciences and Research*, 2(5), pp.308–313.
- Brisse, S., Grimont, F. & Grimont, P.A.D., 2006. The Genus *Klebsiella* Taxonomic History and Structure. *The Prokaryotes*, pp.159–196.
- Deris, Z.Z., Yu, H.H., Davis, K., Soon, R.L., Jacob, J., Ku, C.K. et al., 2012. The combination of colistin and doripenem is synergistic against *Klebsiella pneumoniae* at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. *Antimicrobial Agents and Chemotherapy*, 56(10), pp.5103–5112.
- Dewi, R., 2010. Sepsis pada Anak : Pola Kuman dan Uji Kepekaan. *Majalah Kedokteran Indonesia*, pp.101–106.
- Elek, S.D., 1956. Principles and problems of combined antibiotic therapy. *Postgraduate medical journal*, 32, pp.324–327.
- Fahmey, S.S., 2013. Early-onset sepsis in a neonatal intensive care unit in Beni Suef, Egypt: Bacterial isolates and antibiotic resistance pattern. *Korean Journal of Pediatrics*, 56(8), pp.332–337.
- Fu, Y., Zhang, W., Wang, H., Zhao, S., Chen, Y., Meng, F. et al., 2013. Specific patterns of *gyrA* mutations determine the resistance difference to ciprofloxacin and levofloxacin in *Klebsiella pneumoniae* and *Escherichia coli*. *BMC infectious diseases*, 13(1), p.8. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3576228&tool=pmcentrez&rendertype=abstract>.
- Goldstein, B., Giroir, B. & Randolph, A., 2005. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies*, 6(1), pp.2–8.
- Henriksen, D.P., Laursen, C.B., Pottegård, A. & Hailas, J., 2015. Risk factors for hospitalization due to community-acquired sepsis - A population-based case-control study. *PLoS ONE*, 10(4).

- Hirsch, E.B., Guo, B., Chang, K.T., Cao, H., Ledesma, K.R., Singh, M. et al., 2013. Assessment of antimicrobial combinations for *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *Journal of Infectious Diseases*, 207(5), pp.786–793.
- Hu, F.P., Guo, Y., Zhu, D.M., Wang, F., Jiang, X.F., Xu, Y.C. et al., 2016. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. *Clinical Microbiology and Infection*, 22, pp.S9–S14.
- Jain, S.N., Ramesh, I., Sampath, A. & Narasimhaiah, V.N., 2011. Antibiotic synergy test: Checkerboard method on multidrug resistant *Pseudomonas aeruginosa*. , 2(12), pp.196–198. Available at: [http://www.researchgate.net/publication/237077504\\_Antibiotic\\_synergy\\_test\\_Checkerboard\\_method\\_on\\_multidrug\\_resistant\\_Pseudomonas\\_aeruginosa](http://www.researchgate.net/publication/237077504_Antibiotic_synergy_test_Checkerboard_method_on_multidrug_resistant_Pseudomonas_aeruginosa).
- Jorgensen, J.H. & Ferraro, M.J., 2009. Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices. *Clinical Infectious Diseases*, 7750, pp.1749–1755.
- Katzung, B.G., 2007. Basic & Clinical Pharmacology. , pp.514 – 516.
- Kenneth, J.R. & Ray, C.G., 2004. *Sherri's Medical Microbiology*, Available at: <http://medcontent.metapress.com/index/A65RM03P4874243N.pdf>.
- Korvick, J.A., Bryan, C.S., Farber, B., Beam, T.R., Schenfeld, L., Muder, R.R. et al., 1992. Prospective observational study of *Klebsiella* bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy. *Antimicrobial Agents and Chemotherapy*, 36(12), pp.2639–2644.
- Li, H., Pan, J., Liu, X. et al., 2012. Alterations of protein complexes and pathways in genetic information flow and response to stimulus contribute to *Escherichia coli* resistance to balofloxacin. *Molecular BioSystems*, 8, pp.2303–2311.
- Lusyati, S., van den Broek, P. & Sauer, P.J.J., 2009. Neonatal sepsis in a neonatal intensive care unit in Indonesia. *Journal of Hospital Infection*, 71(4), pp.383–385. Available at: <http://dx.doi.org/10.1016/j.jhin.2009.01.004>.
- Maayan-Metzger, A., Barzilai, A., Keller, N. & Kuint, J., 2009. Are the “good old” antibiotics still appropriate for early-onset neonatal sepsis? A 10 year survey. *Israel Medical Association Journal*, 11(3), pp.138–143.
- Manno, G. et al., 2003. Use of the E test to assess synergy of antibiotic combinations against isolates of *Burkholderia cepacia*-complex from patients with cystic fibrosis. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*, 22(1), pp.28–34.

- Noreddin, A.M., Bush, L.M., Okeh, V., Etienne, J. & Chaparro-Rojas, F., 2011. Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: Critical appraisal and role in therapy. *Infection and Drug Resistance*, 4(1), pp.59–68.
- Papp-Wallace, K.M., Endimiani, A., Taracila, M. & Bomono, R.A., 2011. Carbapenems: Past, present, and future. *Antimicrobial Agents and Chemotherapy*, 55(11), pp.4943–4960.
- Podschun, R. & Ullmann, U., 1998. Klebsiella spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clinical Microbiology Reviews*, 11(4), pp.589–603.
- Polin, R.A., 2012. Management of Neonates With Suspected or Proven Early-Onset Bacterial Sepsis. *Pediatrics*, 129(5), pp.1006–1015. Available at: <http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2012-0541>.
- Polishchuk, A., Chukharev, V.I. & Emelina, T., 2014. Photochemical behavior and photolysis of protonated forms of levofloxacin. *Photochemistry and Photobiology*, 90(1), pp.79–84.
- Rizki, R.L.P., 2015. Studi Efek Kombinasi Meropenem, Gentamisin Dan Levofloxacin Terhadap Isolat Klinis Multidrug Resistance Pseudomonas Aeruginosa (MDR-Pa) Dengan Metode E-test.
- Shah, D. & Narang, M., 2004. Meropenem. *Indian Pediatr*, 42, pp.443–450.
- Sikarwar, A.S. & Batra, H.V., 2011. Prevalence of Antimicrobial Drug Resistance of Klebsiella pneumoniae in India. *International Journal of Bioscience, Biochemistry and Bioinformatics*, 1(3), pp.211–215. Available at: <http://www.ijbbb.org/show-24-299-1.html>.
- Sueke, H., Kaye, S.B., Neal, T., Hall, A., Tuft, S. & Parry, C.M., 2010. An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis. *Investigative Ophthalmology and Visual Science*, 51(8), pp.4151–4155.
- Tängdén, T., 2012. Multidrug-resistant Escherichia coli and Klebsiella pneumoniae: Treatment, Selection and International Spread. *Digital Comprehensive Summaries of Uppsala Disertations from the Faculty of Medicine*, 840, p.72.
- Van belkum, A., Halimi, D., Bonetti, E., Renzi, G., Cherkaoui, A., Sauvonnnet, V. et al., 2015. Meropenem/colistin synergy testing for multidrug-resistant Acinetobacter baumannii strains by a two-dimensional gradient technique applicable in routine microbiology. *Journal of Antimicrobial Chemotherapy*, 70(1), pp.167–172.

- Vergnano, S., 2005. Neonatal sepsis: an international perspective. *Archives of Disease in Childhood - Fetal and Neonatal Edition*, 90(3), pp.F220–f224. Available at: <http://fn.bmj.com/cgi/doi/10.1136/adc.2002.022863>.
- Watson, R.S., Carcillo, J.A., Linde-Zwirble, W.T., Clermont, G., Lidicker, J. & Angus, D.C., 2003. The epidemiology of severe sepsis in children in the United States. *American Journal of Respiratory and Critical Care Medicine*, 167(5), pp.695–701.
- White, R.L., Burgess, D.S., Manduru, M. & Bosso, J.A., 1996. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. *Antimicrobial Agents and Chemotherapy*, 40(8), pp.1914–1918.
- Zhanel, G.G., Simor, A.E., Vercaigne, L. & Mandell, L., 1998. Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. *The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses*, 9(4), pp.215–28. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3250889&tool=pmcentrez&rendertype=abstract>.